Eligibility and key areas of interest

Ventures working in the following areas will be considered high-priority:
  • Therapeutics: broad range of disease indications (e.g., immunology, oncology, neurology, metabolomics) and categories (e.g., small molecules, biologics, cell and gene therapies).
  • Artificial intelligence/machine learning platforms: supporting drug discovery, novel drug screen, discovery, and delivery platforms.
  • Enabling platforms: novel drug screen, discovery, and delivery platforms that can result in a novel drug-related IP. 

Ventures must be:

  • incorporated in Canada
  • be at a pre-clinical stage of development
  • have sufficient funding to reach the next stages of development.
  • At least one person dedicated to the company
  • A patent or provisional patent registration (owned by the university, the inventor or the start-up)
  • An inflection point to be reached within the next 24 months

adMare is committed to equity, diversity, inclusion, and accessibility.


Application process and program duration

Applications for the adMare Tx Accelerator will be accepted on a rolling basis.

Selected companies will be supported by the Accelerator for an initial period of six months. They will then have the option of requesting to extend their participation in the program for a second period of up to 18 months. 


Submission requirements

All interested Canadian ventures* are invited to apply by submitting a non-confidential proposal summary in pptx or PDF format, covering the following criteria:

  • Problem
  • Technology
  • Supporting Data
  • Intellectual Property
  • Market Size
  • Business and technology development plan
  • Team

*Applications are encouraged from Indigenous people, women, people with disabilities, racialized people and 2SLGBTQIA+ people.



Diligence process and key considerations

Under an NDA, selected ventures will undergo a due diligence process prior to finalization, and are expected to grant access to a data room and must directly provide:

  • Scientific results generated to date 
  • Agreements/contracts in place 
  • IP granted/submitted to date
  • Governance and ownership structure
  • List of all investors and private funding 
  • List of all non-dilutive grants obtained

In case you have any questions regarding the application for the National Tx Accelerator Program, please send an email to the Manager of the National Tx Accelerator, Clara Ducord, at

Submit your application

Please apply to only one of the following accelerator locations:

Québec British-Columbia Ontario

Frequently asked

Membership in other commercialization programs or accelerators will be considered on a case by case and in the context of the venture’s plans for technology development and commercialization.

All Canadian-incorporated companies are invited to apply to the Tx Accelerator. However, we only have wet lab and office spaces available in BC, QC, and ON. Please determine which location is best suited for your company.

Upon acceptance to the Tx Accelerator, each company will enter into an agreement outlining the support that will be provided by the program. Acceptance into the accelerator program does not mean that adMare BioInnovations or its regional partners will automatically provide a direct investment (equity) or continuous funding support for your venture. Direct and in-kind support will be provided to each venture depending on the needs determined at intake.

For more information on the adMare Tx Accelerator and how to apply, watch our webinar.


Get in touch today

Virtual office hours are also available Friday between 2-4pm ET.
For additional information or to schedule an appointment, please contact:

Clara Ducord

Manager, National Accelerator